Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MICRO-K 10 vs MICRO-K LS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium is the major intracellular cation; it is essential for the maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function. Potassium chloride is absorbed from the gastrointestinal tract and distributes throughout the body. The microencapsulated formulation allows for gradual release of potassium, minimizing gastrointestinal irritation.
Potassium supplement; replaces intracellular potassium, essential for nerve conduction, muscle contraction, and acid-base balance.
Treatment of hypokalemia,Prevention of hypokalemia in patients receiving digitals or diuretics for congestive heart failure, hepatic cirrhosis, or nephrotic syndrome,Correction of hypokalemia in patients with hypertension on long-term diuretic therapy
Hypokalemia prevention or treatment,Diuretic-induced hypokalemia,Digitalis intoxication
10 m Eq (2 capsules) orally once daily, or 20 m Eq (2 capsules) twice daily, or as directed by physician. Maximum 100 m Eq/day.
10-20 m Eq (as potassium chloride) orally twice daily; maximum 100 m Eq/day.
Not applicable; potassium is not cleared by first-order kinetics. Whole-body potassium turnover half-life is approximately 30 days, but this is not clinically relevant for supplementation.
Not applicable (K+ is an electrolyte, not eliminated by first-order kinetics). Clinical context: Serum K+ decline follows redistribution and excretion with a half-life of ~2-4 hours after IV bolus.
Potassium is not metabolized. Approximately 90% of ingested potassium is excreted in the urine, with the remainder excreted in feces and sweat. There is no hepatic metabolism.
Not metabolized; excreted primarily via kidneys.
Primarily renal: 90% of absorbed potassium is excreted in urine as potassium ions; 10% eliminated in feces via biliary and intestinal secretion.
Renal: ~90% as KCl (proportional to intake). Biliary/fecal: <10%.
0% bound to serum proteins; free ion in serum.
None (K+ is free ion).
Total body water: 0.5 L/kg; distributes primarily intracellularly (98% of body potassium is intracellular), but Vd is not a clinically relevant parameter for potassium.
0.35 L/kg (approximate total body water; distributes primarily in extracellular fluid).
Oral (microencapsulated): 90-100% relative to intravenous; absorption is nearly complete via the gastrointestinal tract.
Oral: ~80-100% for microencapsulated KCl (MICRO-K), but can be incomplete due to slower release.
GFR >50 m L/min: no adjustment. GFR 10-50 m L/min: reduce dose by 50% or use with caution. GFR <10 m L/min: contraindicated or use with extreme caution.
GFR 50-90 m L/min: no adjustment. GFR 30-49 m L/min: reduce dose by 25-50%. GFR <30 m L/min: avoid use or reduce dose by 50-75% with close monitoring.
No specific Child-Pugh based modifications; use with caution in severe hepatic impairment due to risk of hyperkalemia.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 25-50%. Child-Pugh C: avoid use or reduce dose by 50%.
Children: 1-2 m Eq/kg/day in divided doses, not to exceed 20 m Eq per dose or 100 m Eq/day. Minimum dosing weight not specified; safety and efficacy not established in premature infants.
1-3 m Eq/kg/day orally in 2-4 divided doses; maximum 1 m Eq/kg per dose and 100 m Eq/day.
Elderly: start with lower doses (e.g., 10 m Eq once daily) due to age-related renal function decline; monitor serum potassium and renal function frequently.
Initiate at lower end of dosing range (10-20 m Eq/day); monitor renal function and serum potassium frequently; adjust based on renal function.
None
No black box warning.
Hyperkalemia risk; use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia,Gastrointestinal irritation and ulceration; do not crush or chew tablets,May increase serum potassium levels in patients with adrenal insufficiency or diabetes,Use caution with potassium-sparing diuretics or ACE inhibitors
Risk of hyperkalemia especially in renal impairment,Use with caution in cardiac disease,GI irritation or ulceration with oral forms,Slow release formulations may cause GI lesions
Severe renal impairment with oliguria or azotemia,Addison's disease,Acute dehydration,Heat cramps,Hyperkalemia from any cause,Concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride)
Hyperkalemia,Severe renal impairment,Untreated Addison's disease,Acute dehydration,Use of potassium-sparing diuretics
Avoid high-potassium foods (e.g., bananas, oranges, tomatoes, potatoes, salt substitutes) unless directed otherwise; intake may need to be restricted or monitored.
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, potatoes, spinach, avocados, dried fruits, salt substitutes containing potassium chloride). Do not take with alcohol as it may increase GI irritation. Grapefruit juice has no significant interaction, but large amounts of any food high in potassium should be avoided.
Potassium chloride is not associated with fetal malformations. In all trimesters, excessive potassium intake can cause maternal hyperkalemia, which may lead to fetal arrhythmias or adverse outcomes. Recommended intakes are safe.
MICRO-K LS (potassium chloride) is not associated with teratogenicity. No fetal risks have been reported in any trimester. Use during pregnancy is considered safe when indicated.
Potassium is a normal constituent of breast milk with an M/P ratio of approximately 0.1-0.2. Supplemental potassium is not expected to cause adverse effects in nursing infants at usual maternal doses.
Potassium is a normal component of breast milk. No adverse effects expected at maternal therapeutic doses. M/P ratio: not applicable (endogenous electrolyte).
No specific dose adjustment required for pregnancy. However, increased plasma volume and renal blood flow during pregnancy may lower serum potassium, potentially requiring higher doses for hypokalemia treatment. Individualize based on serum potassium monitoring.
No dose adjustment typically required. Maintain serum potassium within normal range. Monitor for hypokalemia or hyperkalemia as clinically indicated.
Micro-K 10 (potassium chloride extended-release) is used for hypokalemia. Avoid in severe renal impairment (Cr Cl <30 m L/min) due to risk of hyperkalemia. Do not crush or chew capsules; administer with food to reduce GI irritation. Monitoring serum potassium levels is essential, especially in patients on digoxin or diuretics. Use with caution in patients with significant heart block or metabolic acidosis.
MICRO-K LS contains potassium chloride microencapsulated granules for sustained release. Avoid in patients with severe renal impairment (Cr Cl <30 m L/min), untreated Addison's disease, or hyperkalemia. Use with caution in patients with cardiac disease or concurrent use of ACE inhibitors, ARBs, or potassium-sparing diuretics. Do not crush or chew capsules; administer with a full glass of water to prevent GI mucosal damage. Monitor serum potassium regularly, especially in elderly and diabetic patients.
Take this medication exactly as prescribed, usually once daily with food.,Do not crush, chew, or open the capsule; swallow whole.,Do not use salt substitutes or potassium supplements unless instructed by your doctor.,Seek medical attention if you experience muscle weakness, irregular heartbeat, or signs of GI obstruction (severe stomach pain, vomiting, or black stools).,Tell your doctor about all medications, especially diuretics or ACE inhibitors.
Take this medication exactly as prescribed, preferably with meals or a full glass of water.,Do not crush, chew, or break the capsules; swallow them whole.,Avoid foods high in potassium (e.g., bananas, oranges, tomatoes, salt substitutes) unless directed by your doctor.,Contact your doctor immediately if you experience muscle weakness, irregular heartbeat, numbness/tingling, or dark/tarry stools.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MICRO-K 10 vs MICRO-K LS, answered by our medical review team.
MICRO-K 10 is a Electrolyte Supplement (Potassium) that works by Potassium is the major intracellular cation; it is essential for the maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function. Potassium chloride is absorbed from the gastrointestinal tract and distributes throughout the body. The microencapsulated formulation allows for gradual release of potassium, minimizing gastrointestinal irritation.. MICRO-K LS is a Electrolyte Supplement (Potassium) that works by Potassium supplement; replaces intracellular potassium, essential for nerve conduction, muscle contraction, and acid-base balance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MICRO-K 10 and MICRO-K LS depend on the specific clinical indication. These are both Electrolyte Supplement (Potassium) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MICRO-K 10 is: 10 m Eq (2 capsules) orally once daily, or 20 m Eq (2 capsules) twice daily, or as directed by physician. Maximum 100 m Eq/day.. The standard adult dose of MICRO-K LS is: 10-20 m Eq (as potassium chloride) orally twice daily; maximum 100 m Eq/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MICRO-K 10 and MICRO-K LS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MICRO-K 10 is classified as Category C. Potassium chloride is not associated with fetal malformations. In all trimesters, excessive potassium intake can cause maternal hyperkalemia, which may lead to fetal arrhythmias or. MICRO-K LS is classified as Category C. MICRO-K LS (potassium chloride) is not associated with teratogenicity. No fetal risks have been reported in any trimester. Use during pregnancy is considered safe when indicated.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.